Clearance of amyloid-beta by circulating lipoprotein receptors - PubMed (original) (raw)
. 2007 Sep;13(9):1029-31.
doi: 10.1038/nm1635. Epub 2007 Aug 12.
Rashid Deane, Robert D Bell, Bradley Johnson, Katie Hamm, Ronan Pendu, Andrew Marky, Peter J Lenting, Zhenhua Wu, Troy Zarcone, Alison Goate, Kevin Mayo, David Perlmutter, Mireia Coma, Zhihui Zhong, Berislav V Zlokovic
Affiliations
- PMID: 17694066
- PMCID: PMC2936449
- DOI: 10.1038/nm1635
Clearance of amyloid-beta by circulating lipoprotein receptors
Abhay Sagare et al. Nat Med. 2007 Sep.
Abstract
Low-density lipoprotein receptor-related protein-1 (LRP) on brain capillaries clears amyloid beta-peptide (Abeta) from brain. Here, we show that soluble circulating LRP (sLRP) provides key endogenous peripheral 'sink' activity for Abeta in humans. Recombinant LRP cluster IV (LRP-IV) bound Abeta in plasma in mice and Alzheimer's disease-affected humans with compromised sLRP-mediated Abeta binding, and reduced Abeta-related pathology and dysfunction in a mouse model of Alzheimer disease, suggesting that LRP-IV can effectively replace native sLRP and clear Abeta.
Figures
Figure 1
LRP-IV clears mouse endogenous brain Aβ improves function and clears human brain Aβ in APP+/sw mice. (a,b) Brain levels (a) and total plasma levels (b) of mouse endogenous Aβ40 and Aβ42 in vehicle-treated (white) and LRP-IV-treated (intravenously for 5 d, 20 µg/day) mice (black) Values are means ± s.e.m., n = 3–5 mice per group. (c) Percent increase in cerebral blood flow (CBF) in response to whisker stimulation in littermate controls (gray) and APP+/sw mice treated with vehicle (white) or LRP-IV (black). (d–f) Operant learning at day 1 and 2 (d), novel object location (e) and novel object recognition (f) expressed as percentage exploratory preference in littermate controls (gray) and APP+/sw mice treated with vehicle (white) or LRP-IV (black). (g,h) Aβ40 and Aβ42 levels in hippocampus (g) and cortex (h) of APP+/sw mice treated with vehicle or LRP-IV. In c–h, LRP-IV (40 µg per kg body weight per day) was administered intraperitioneally for 3 months beginning at age 6 months. Values are means ± s.e.m., n = 8 mice per group. All procedures with wild-type mice and APP+/sw mice were according to US NIH guidelines approved by the University Committee on Animal Resources, University of Rochester.
Figure 2
LRP-IV controls Aβ pathology in APP+/sw mice and sLRP and LRP-IV regulate peripheral Aβ in Alzheimer’s disease. (a) Aβ immunostaining in APP+/sw mice treated with vehicle or LRP-IV. (b) X-34 staining for amyloid (blue) and CD31 immunostaning for vascular endothelium (red) in APP+/sw mice treated with vehicle or LRP-IV. Insets: left, amyloid in the pial vessel on the surface of the brain in vehicle-treated mice; right, absence of amyloid in the pial vessel in LRP-IV treated mice. (c) Total plasma Aβ40 and Aβ42 levels in vehicle-treated (white bars) and LRP-IV-treated (black bars) mice. In a–c, LRP-IV (40 µg per kg body weight per day) was administered intraperitoneally for 3 months beginning at the age of 6 months. Values are means ± s.e.m., n = 8 mice per group. (d) Plasma sLRP levels in individuals without (non-AD; white) and with (AD; black) Alzheimer’s disease. Means ± s.e.m., from 36 non-AD and 44 AD individuals. (e) Oxidized sLRP (carbonyl content) in plasma of non-AD (white) and AD (black) individuals. Means ± s.e.m. from 12 non-AD and 16 AD individuals. (f,g) sLRP-bound Aβ40 and Aβ42, free Aβ40 and Aβ42 (<30 kDa), and Aβ40 and Aβ42 associated with other plasma proteins (>30 kDa) in non-AD controls (white) and AD individuals (black). Means ± s.e.m., n = 18 per group. (h) Effect of LRP-IV on redistribution of different Aβ40 and Aβ42 pools in AD plasma. Means ± s.e.m., n = 6. All procedures with AD mice were according to the NIH guidelines approved by the University Committee on Animal Resources, University of Rochester. The experiments involving human subjects have been approved by the Institutional Review Board Committee of the Washington University School of Medicine through the Alzheimer’s Disease Research Center. Informed consent was obtained from all subjects.
Similar articles
- The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.
Deane R, Sagare A, Zlokovic BV. Deane R, et al. Curr Pharm Des. 2008;14(16):1601-5. doi: 10.2174/138161208784705487. Curr Pharm Des. 2008. PMID: 18673201 Free PMC article. Review. - Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.
Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V. Sehgal N, et al. Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3510-5. doi: 10.1073/pnas.1112209109. Epub 2012 Jan 30. Proc Natl Acad Sci U S A. 2012. PMID: 22308347 Free PMC article. - Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
Deane R, Bell RD, Sagare A, Zlokovic BV. Deane R, et al. CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. doi: 10.2174/187152709787601867. CNS Neurol Disord Drug Targets. 2009. PMID: 19275634 Free PMC article. Review. - Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease.
Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O. Jaya Prasanthi RP, et al. Mech Ageing Dev. 2008 Nov;129(11):649-55. doi: 10.1016/j.mad.2008.09.002. Epub 2008 Sep 19. Mech Ageing Dev. 2008. PMID: 18845178 Free PMC article. - Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway.
Yoon IS, Chen E, Busse T, Repetto E, Lakshmana MK, Koo EH, Kang DE. Yoon IS, et al. FASEB J. 2007 Sep;21(11):2742-52. doi: 10.1096/fj.07-8114com. Epub 2007 Apr 26. FASEB J. 2007. PMID: 17463224
Cited by
- Trajectory of brain-derived amyloid beta in Alzheimer's disease: where is it coming from and where is it going?
Liu N, Haziyihan A, Zhao W, Chen Y, Chao H. Liu N, et al. Transl Neurodegener. 2024 Aug 19;13(1):42. doi: 10.1186/s40035-024-00434-9. Transl Neurodegener. 2024. PMID: 39160618 Free PMC article. Review. - Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer's patients: A double-blind placebo-controlled randomized clinical trial.
Rustamzadeh A, Sadigh N, Vahabi Z, Khamseh F, Mohebi N, Ghobadi Z, Moradi F. Rustamzadeh A, et al. IBRO Neurosci Rep. 2024 Jul 20;17:108-121. doi: 10.1016/j.ibneur.2024.07.002. eCollection 2024 Dec. IBRO Neurosci Rep. 2024. PMID: 39139290 Free PMC article. - Blood-brain barrier disruption: a culprit of cognitive decline?
Che J, Sun Y, Deng Y, Zhang J. Che J, et al. Fluids Barriers CNS. 2024 Aug 7;21(1):63. doi: 10.1186/s12987-024-00563-3. Fluids Barriers CNS. 2024. PMID: 39113115 Free PMC article. Review. - Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer's Disease.
Petralla S, Panayotova M, Franchina E, Fricker G, Puris E. Petralla S, et al. Pharmaceutics. 2024 Jul 17;16(7):948. doi: 10.3390/pharmaceutics16070948. Pharmaceutics. 2024. PMID: 39065645 Free PMC article. Review. - Intermittent hypoxia training enhances Aβ endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer's disease.
Wang X, Xie Y, Fan X, Wu X, Wang D, Zhu L. Wang X, et al. Alzheimers Res Ther. 2024 Jun 3;16(1):121. doi: 10.1186/s13195-024-01489-6. Alzheimers Res Ther. 2024. PMID: 38831312 Free PMC article.
References
- Deane R, et al. Neuron. 2004;43:333–344. - PubMed
- Tanzi RE, Moir RD, Wagner SL. Neuron. 2004;43:605–608. - PubMed
- Tamaki C, et al. Pharm. Res. 2006;23:1407–1416. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 AG05681/AG/NIA NIH HHS/United States
- R37 NS034467/NS/NINDS NIH HHS/United States
- R37 NS34467/NS/NINDS NIH HHS/United States
- R37 AG023084/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- R01 NS034467/NS/NINDS NIH HHS/United States
- R01 NS034467-07/NS/NINDS NIH HHS/United States
- R37 AG023084-02/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous